Chune Q. Dong

Wuhan, 430071, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer.

Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer.

Journal: Journal of medicinal chemistry

Published: July 07, 2026

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer.

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer.

Journal: European journal of medicinal chemistry

Published: February 26, 2026

A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α.

A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α.

Journal: Journal of medicinal chemistry

Published: February 15, 2026

Hydrophobic Tag Degraders Overcome Endocrine-Resistant Breast Cancer by Recruiting HSP27-Mediated E3 Ligase Complex for ERα Proteasomal Degradation.

Hydrophobic Tag Degraders Overcome Endocrine-Resistant Breast Cancer by Recruiting HSP27-Mediated E3 Ligase Complex for ERα Proteasomal Degradation.

Journal: Angewandte Chemie (International ed. in English)

Published: November 21, 2025

Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression.

Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression.

Journal: Journal of medicinal chemistry

Published: November 11, 2025

Hydrophobic tagging: A promising paradigm for targeted protein degradation.

Hydrophobic tagging: A promising paradigm for targeted protein degradation.

Journal: Cell insight

Published: September 28, 2025

Targeted degradation of estrogen receptor β to overcome Osimertinib resistance in non-small cell lung carcinoma.

Targeted degradation of estrogen receptor β to overcome Osimertinib resistance in non-small cell lung carcinoma.

Journal: Bioorganic chemistry

Published: August 04, 2025

The novel SIRT2-targeted PROTAC degraders as the efficient agents for the treatment of ovarian cancer.

The novel SIRT2-targeted PROTAC degraders as the efficient agents for the treatment of ovarian cancer.

Journal: European journal of medicinal chemistry

Published: June 25, 2025

Targeted Degradation of the Estrogen Receptor α through Unconventional Coactivator Binding Site (CBS).

Targeted Degradation of the Estrogen Receptor α through Unconventional Coactivator Binding Site (CBS).

Journal: Journal of medicinal chemistry

Published: June 17, 2025

Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer.

Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer.

Journal: Journal of medicinal chemistry

Published: May 28, 2025

Discovery of ERα-targeting PROTACs with intrinsic fluorescence for precision theranostics of breast cancer.

Discovery of ERα-targeting PROTACs with intrinsic fluorescence for precision theranostics of breast cancer.

Journal: RSC medicinal chemistry

Published: April 02, 2025

Pegylated NIR Fluorophore-Conjugated OBHSA Prodrug for ERα-Targeted Theranostics with Enhanced Imaging and Long-Term Retention.

Pegylated NIR Fluorophore-Conjugated OBHSA Prodrug for ERα-Targeted Theranostics with Enhanced Imaging and Long-Term Retention.

Journal: Molecules (Basel, Switzerland)

Published: November 07, 2024

Showing 1-12 of 67

Last Updated: 09/26/2026